Reviewed by Shameer Deen, ST5 Urology Registrar
Antimicrobial resistance (AMR) is one of the defining public health crises of our era. The World Health Organization estimates that drug-resistant infections directly caused 1.27 million deaths globally in 2019, and without intervention that figure could rise to 10 million per year by 2050 [1]. Every unnecessary or inappropriately chosen antibiotic prescription accelerates this trajectory. Antibiotic stewardship is the structured response — a set of coordinated strategies to optimise antibiotic use, improve patient outcomes, and slow resistance.
What Is Antibiotic Stewardship?
Antibiotic stewardship encompasses any effort to measure and improve how antibiotics are prescribed and used. At the individual prescriber level it means choosing the right drug, at the right dose, for the right duration, in the right patient. At the institutional level it involves formal programmes with microbiologists, pharmacists, and infection specialists reviewing prescribing patterns and feeding back to clinical teams [2].
The O'Neill Review on AMR (2016) — the landmark independent analysis commissioned by the UK government — identified stewardship as one of the most cost-effective interventions available, estimating that a global campaign to reduce unnecessary antibiotic use could save $100 trillion in economic output by 2050 while preventing tens of millions of deaths [2].
Narrow-Spectrum vs. Broad-Spectrum: The Core Decision
Choosing between narrow- and broad-spectrum antibiotics is the most consequential decision in stewardship. Broad-spectrum agents cover a wide range of bacterial species and are tempting when a diagnosis is uncertain, but they carry a heavy cost [1]:
- They disrupt the commensal microbiome, selecting for resistant organisms including Clostridioides difficile
- They drive collateral resistance in bacteria that were not the target of treatment
- They encourage prescribers to avoid the diagnostic work needed to identify the causative organism
The stewardship principle is to use the narrowest effective spectrum. For community-acquired urinary tract infections caused by E. coli, nitrofurantoin or trimethoprim will suffice in most cases — there is no stewardship justification for reaching immediately for co-amoxiclav or ciprofloxacin.
The Five Key Principles of Stewardship
1. Diagnose Before You Prescribe
Send cultures before starting antibiotics wherever possible. Blood cultures, urine cultures, wound swabs, and sputum samples take minutes to collect but provide data that can guide therapy for the entire course [1]. Starting empirical therapy is often appropriate, but diagnostic samples must come first.
2. Follow Local Empirical Guidelines
Resistance patterns vary significantly between hospitals, regions, and countries. Local empirical guidelines, developed using surveillance data from the institution's own microbiology laboratory, represent the best evidence for what will work in your patient population. Using agents outside these guidelines without specialist input risks both treatment failure and unnecessary broad-spectrum exposure.
3. Review at 48-72 Hours
The 48-72 hour review is the most important stewardship intervention in inpatient care. When culture results return, reassess: Is the antibiotic appropriate? Can therapy be de-escalated to a narrower agent? Can the patient switch from intravenous to oral? Can the course be shortened? [2] Each of these questions saves cost, reduces adverse effects, and slows resistance.
4. De-escalate Actively
De-escalation — stepping down from broad to narrow spectrum once culture results allow — is not the default behaviour of most prescribers. Inertia keeps patients on their initial empirical therapy even when microbiology confirms a sensitive organism that would respond to a narrower agent. Active de-escalation requires deliberate effort but is one of the most impactful stewardship behaviours [1].
5. Respect Duration Limits
Longer is not safer. Evidence-based evidence across multiple infection types has consistently shown that shorter courses achieve equivalent cure rates with less microbiome disruption and lower resistance selection pressure [2]. Five days of appropriate antibiotics for uncomplicated community-acquired pneumonia performs as well as ten days in most patients.
How MedNext Supports Stewardship
MedNext Formulary's antibiotic monographs from the MedNext Audited Proprietary Dataset include spectrum-of-activity information, recommended course durations, and notes on when de-escalation is appropriate. The interaction checker flags combinations that increase resistance risk or toxicity. Together these tools support point-of-care stewardship decisions without requiring a separate guideline lookup.
References
- World Health Organization. Antimicrobial Resistance: Global Report on Surveillance. WHO, 2024.
- O'Neill J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. The Review on Antimicrobial Resistance, 2016.